Get the Stockscreener App
4.61
0.66%
0.03
Amylyx Pharmaceuticals Inc stock is traded at $4.61, with a volume of 982.52K.
It is up +0.66% in the last 24 hours and up +32.09% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$4.58
Open:
$4.51
24h Volume:
982.52K
Relative Volume:
1.17
Market Cap:
$473.93M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
6.5857
EPS:
0.7
Net Cash Flow:
$10.68M
1W Performance:
-13.35%
1M Performance:
+32.09%
6M Performance:
-31.19%
1Y Performance:
+143.92%
1-Day Range:
$4.405
$4.82
1-Week Range:
$4.405
$5.36
52-Week Range:
$1.575
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
4.61 | 473.93M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AMLX) - Seeking Alpha
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX - ACCESS Newswire
Amylyx Pharmaceuticals (AMLX) Target Price Raised by HC Wainwrig - GuruFocus
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Leerink Partnrs - Defense World
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by Leerink Partners - Defense World
Amylyx Pharmaceuticals Advances Clinical Trials and Strengthens Finances - TipRanks
Amylyx Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX)April 9, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Mariner LLC Decreases Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : Amylyx Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
This Biotech Found Mid-Week Success Following Analyst Upgrade - The Globe and Mail
Amylyx Pharmaceuticals Shares Rise After Upgrade From Leerink - marketscreener.com
Amylyx Pharmaceuticals (AMLX) Rating Upgraded by Leerink Partner - GuruFocus
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences - BioSpace
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Leerink Partners Upgrades Amylyx Pharmaceuticals (AMLX) - Nasdaq
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Tower Research Capital LLC TRC Has $174,000 Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals (AMLX) Projected to Post Earnings on Thursday - Defense World
Amylyx (AMLX) Upgraded as Avexitide Gains Momentum | AMLX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by JPMorgan Chase & Co. - Defense World
UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
This trade activity should not be overlooked: Amylyx Pharmaceuticals Inc (AMLX) - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
Investor’s Delight: Amylyx Pharmaceuticals Inc (AMLX) Closes Strong at 5.11, Up 4.29 - DWinneX
Amylyx doses first subject in trial of post-bariatric hypoglycaemia treatment - Yahoo Finance
Amylyx (AMLX) Begins Phase 3 Trial for Post-Bariatric Hypoglycem - GuruFocus
Potential Price Increase for Amylyx Pharmaceuticals Inc (AMLX) After Recent Insider Activity - knoxdaily.com
Amylyx Pharmaceuticals Starts Dosing in Phase 3 Trial for Post-Bariatric Hypoglycemia Treatment - marketscreener.com
Amylyx Pharmaceuticals Inc (AMLX) stock: A year of ups and downs - uspostnews.com
Amylyx (AMLX) Begins Phase 3 Trial for Post-Bariatric Hypoglycemia Treatment | AMLX Stock News - GuruFocus
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx starts Phase 3 trial for hypoglycemia treatment By Investing.com - Investing.com India
Amylyx starts Phase 3 trial for hypoglycemia treatment - Investing.com
Amylyx Pharmaceuticals Announces First Participant Dosed In Pivotal Phase 3 Lucidity Trial Of Avexitide In Post-Bariatric Hypoglycemia - marketscreener.com
Guggenheim Capital LLC Has $136,000 Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Geode Capital Management LLC Grows Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
AMLX’s Stock Journey: What Investors Need to Know About Amylyx Pharmaceuticals Inc’s Performance - investchronicle.com
Amylyx Pharma Gearing Up For FDA Decision - RTTNews
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Stock Surge: Amylyx Pharmaceuticals Inc (AMLX) Closes at 3.00, Marking a -9.09 Increase/Decrease - DWinneX
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):